Susquehanna International Group’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$300K Sell
177,500
-204,800
-54% -$422K ﹤0.01% 10857
2025
Q4
$757K Buy
382,300
+242,000
+172% +$775K ﹤0.01% 7844
2025
Q3
$408K Sell
140,300
-107,200
-43% -$247K ﹤0.01% 9428
2025
Q2
$448K Sell
247,500
-61,000
-20% -$109K ﹤0.01% 9431
2025
Q1
$463K Sell
308,500
-2,189,800
-88% -$5.53M ﹤0.01% 9064
2024
Q4
$5.9M Buy
2,498,300
+1,079,200
+76% +$19M ﹤0.01% 3357
2024
Q3
$41.8M Buy
1,419,100
+987,900
+229% +$22.8M 0.01% 1213
2024
Q2
$5.33M Buy
431,200
+288,700
+203% +$6.09M ﹤0.01% 3342
2024
Q1
$2.89M Sell
142,500
-239,700
-63% -$5.52M ﹤0.01% 4595
2023
Q4
$8.6M Sell
382,200
-83,900
-18% -$1.77M ﹤0.01% 2835
2023
Q3
$7.76M Buy
466,100
+167,400
+56% +$3.32M ﹤0.01% 2884
2023
Q2
$7.32M Sell
298,700
-11,000
-4% -$265K ﹤0.01% 2936
2023
Q1
$7.47M Sell
309,700
-351,500
-53% -$9.74M ﹤0.01% 2872
2022
Q4
$19.5M Sell
661,200
-246,900
-27% -$8.87M ﹤0.01% 1545
2022
Q3
$38M Buy
908,100
+213,500
+31% +$5.77M 0.01% 973
2022
Q2
$19.5M Sell
694,600
-233,200
-25% -$5.89M ﹤0.01% 1471
2022
Q1
$34.5M Sell
927,800
-224,300
-19% -$9.5M 0.01% 1242
2021
Q4
$50.3M Sell
1,152,100
-374,200
-25% -$19.6M 0.01% 1087
2021
Q3
$94.8M Buy
1,526,300
+1,024,200
+204% +$85.5M 0.01% 806
2021
Q2
$42.9M Buy
502,100
+53,100
+12% +$2.84M 0.01% 1311
2021
Q1
$20.2M Buy
449,000
+192,400
+75% +$7.57M ﹤0.01% 1858
2020
Q4
$1.75M Buy
256,600
+135,600
+112% +$1.21M ﹤0.01% 5381
2020
Q3
$1.39M Sell
121,000
-16,300
-12% -$73.5K ﹤0.01% 5331
2020
Q2
$423K Buy
137,300
+89,400
+187% +$405K ﹤0.01% 7721
2020
Q1
$197K Buy
+47,900
New +$317K ﹤0.01% 8714
2014
Q1
Sell
-3,000
Closed -$102K 9347
2013
Q4
$102K Buy
3,000
+43
+1% +$1.14K ﹤0.01% 8629
2013
Q3
$56K Buy
+2,957
New +$51.7K ﹤0.01% 8209

Other funds holding FLNA

Susquehanna International Group's FLNA Position: Q1 2026 in Review

Susquehanna International Group reduced its Filana Therapeutics (FLNA) stake by 15% in Q1 2026, selling an estimated $166K and leaving 447,278 shares worth $756K. The position accounts for ﹤0.01% of the portfolio, ranked #8619.

Susquehanna International Group first reported a position in FLNA in Q2 2013 and has held it in 49 quarters since. The position peaked at $30M in Q2 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Susquehanna International Group held 447,278 shares of Filana Therapeutics worth $756K as of Q1 2026.
  • Susquehanna International Group sold 80,740 Filana Therapeutics shares in Q1 2026, an estimated $166K.
  • Filana Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8619 holding.
  • Susquehanna International Group first reported a position in Filana Therapeutics in Q2 2013 and has held it in 49 quarters since.
  • Susquehanna International Group's Filana Therapeutics position peaked at $30M in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.